Intercept Pharmaceuticals

220 articles with Intercept Pharmaceuticals

• Intercept Announces FDA Advisory Committee Meeting Date for Obeticholic Acid as a Treatment for Pre-Cirrhotic Liver Fibrosis due to NASH

  3/10/2023

  Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT) today announced that the Gastrointestinal Drugs Advisory Committee (GIDAC) of the U.S. Food and Drug Administration (FDA) will discuss Intercept’s new drug application (NDA) for obeticholic acid (OCA) as a treatment for pre-cirrhotic liver fibrosis due to nonalcoholic steatohepatitis (NASH) on May 19, 2023.

• Intercept Pharmaceuticals to Conduct One-on-One Meetings with Investors at the Barclays Global Healthcare Conference March 14, 2023

  3/9/2023

  Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that it will be participating in investor meetings at the Barclays Global Healthcare Conference at the Loews Miami Beach Hotel on March 14, 2023. 

• Intercept Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Updates; Issues 2023 Financial Guidance

  3/2/2023

  Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced its financial results for the fourth quarter and full year ended on December 31, 2022.

• Intercept Pharmaceuticals to Participate in Cowen’s 43rd Annual Health Care Conference on March 7, 2023 

  2/27/2023

  Intercept Pharmaceuticals, Inc. today announced that Jerry Durso, President and Chief Executive Officer of Intercept, and Andrew Saik, Chief Financial Officer of Intercept, will participate in a fireside chat at Cowen’s 43rd Annual Health Care Conference, taking place in person on Tuesday, March 7, 2023.

• Intercept to Announce Fourth Quarter and Full Year 2022 Financial Results on March 2, 2023

  2/23/2023

  Intercept Pharmaceuticals, Inc. will announce its fourth quarter and full-year 2022 financial results on Thursday, March 2, 2023.

• FDA Accepts Intercept’s New Drug Application for OCA for the Treatment of Pre-Cirrhotic Liver Fibrosis Due to NASH

  1/19/2023

  Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT) today announced that the U.S. Food and Drug Administration (FDA) has accepted Intercept’s New Drug Application (NDA) for obeticholic acid (OCA) seeking accelerated approval for the treatment of patients with pre-cirrhotic liver fibrosis due to nonalcoholic steatohepatitis (NASH).

• Intercept Pharmaceuticals to Present at J.P. Morgan 41st Annual Healthcare Conference on January 12, 2023

  1/5/2023

  Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT) today announced that Jerry Durso, President and Chief Executive Officer, will give a corporate presentation at the J.P. Morgan 41st Annual Healthcare Conference.

• Intercept Announces Efficacy and Safety Data from Phase 3 REGENERATE Study in Liver Fibrosis due to NASH to be Presented at NASH-TAG Conference 2023

  1/4/2023

  Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced two abstracts on obeticholic acid (OCA) will be presented at the NASH-TAG Conference 2023.

• Intercept Resubmits New Drug Application to U.S. FDA for Obeticholic Acid in Patients with Liver Fibrosis due to NASH

  12/23/2022

  Intercept Pharmaceuticals, Inc. today announced that it has resubmitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for obeticholic acid (OCA) for the treatment of patients with pre-cirrhotic liver fibrosis due to nonalcoholic steatohepatitis (NASH).

• New Study Published in The American Journal of Pathology Suggests Obeticholic Acid (OCA) May Improve Cognitive Impairment Associated with Cholestatic Liver Disease

  12/8/2022

  Intercept Pharmaceuticals, Inc. is pleased to share that The American Journal of Pathology has published results of a new study evaluating the link between cholestatic liver disease and cognitive impairment in mouse and human cell models.

• Intercept Pharmaceuticals to Participate in Piper Sandler’s 34th Annual Healthcare Conference on December 1, 2022 

  11/22/2022

  Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT) today announced that Jerry Durso, President and Chief Executive Officer of Intercept, and Andrew Saik, Chief Financial Officer of Intercept, will participate in a fireside chat at Piper Sandler’s 34th Annual Healthcare Conference, taking place in person on Thursday, December 1, 2022.

• TES Pharma Congratulates Intercept Pharmaceuticals on their Presentation of Phase 1 INT-787 Data at the AASLD Meeting and the Initiation of the Phase 2a FRESH Study in Patients with Severe Alcohol-Associated Hepatitis

  11/8/2022

  TES Pharma Srl, an Italian biotechnology company focused on the discovery and development of novel drug products for the treatment of diseases of high unmet medical need, congratulates Intercept Pharmaceuticals, Inc., on the presentation of data from their ongoing first-in-human study of INT-787 and the initiation of the phase 2a FRESH study, a trial evaluating the safety, tolerability, efficacy and pharmacokinetics of INT-787 in subjects with sAH.

• Intercept Announces Development Program for Next-Generation FXR Agonist INT-787 in Severe Alcohol-Associated Hepatitis

  11/7/2022

  Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced plans to focus development of its next-generation FXR agonist, INT-787, in severe alcohol-associated hepatitis (sAH).

• Intercept Announces Additional Positive Data in Fibrosis due to NASH from New Analysis of Phase 3 REGENERATE Study at AASLD The Liver Meeting® 2022

  11/7/2022

  Intercept Pharmaceuticals, Inc. announced additional supportive data from its pivotal Phase 3 REGENERATE study of obeticholic acid in patients with liver fibrosis due to nonalcoholic steatohepatitis.

• Intercept Announces Two Analyses Demonstrating Improvement in Outcomes, Including Transplant-Free Survival, for PBC Patients Treated with OCA to be Presented at AASLD The Liver Meeting® 2022

  11/6/2022

  Intercept Pharmaceuticals, Inc. announced that results from two analyses assessing the potential of obeticholic acid to improve outcomes for patients with primary biliary cholangitis, including death, liver transplant and hepatic decompensation, will be presented at The Liver Meeting®, the annual meeting of the American Association for the Study of Liver Diseases.

• Intercept Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business Update

  11/1/2022

  Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced its financial results for the quarter ended September 30, 2022.

• Intercept Announces New Data to be Presented in PBC, Liver Fibrosis due to NASH and Pipeline at AASLD The Liver Meeting® 2022

  10/31/2022

  Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced multiple abstracts on obeticholic acid (OCA) and INT-787, a next-generation FXR agonist, will be presented at The Liver Meeting® 2022.

• Intercept to Announce Third Quarter 2022 Financial Results on November 1, 2022

  10/25/2022

  Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, will announce its third quarter 2022 financial results prior to market open on Tuesday, November 1, 2022.

• Intercept Pharmaceuticals to Participate in H.C. Wainwright’s 6th Annual NASH Investor Conference on October 17, 2022

  10/12/2022

  Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that Jerry Durso, President and Chief Executive Officer, and Dr. Michelle Berrey, President of R&D and Chief Medical Officer of Intercept will participate in a fireside chat at H.C. Wainwright’s 6th Annual NASH Investor Conference.

• 

  Intercept Strikes Out in Phase III NASH Trial

  10/3/2022

  Intercept Pharmaceuticals' Ocaliva failed to treat patients with compensated cirrhosis due to nonalcoholic steatohepatitis better than a placebo in a Phase III trial, the company announced Friday.